Latin Foods Market sold Artri King Reforzado con Ortiga y Omega 3, an unapproved drug with undeclared diclofenac and dexamethasone.
What happened
FDA purchased a sample of Artri King Reforzado con Ortiga y Omega 3 through Latin Foods Market's website and reviewed its labeling. Laboratory analysis confirmed the product contained diclofenac and dexamethasone, which were not declared on the label. The label also made drug claims, such as that it fights arthritis and is anti-inflammatory and analgesic.
What FDA found
The product is an unapproved new drug—a drug without FDA approval—because it claims to treat arthritis and joint problems.
FD&C Act section 505(a), 21 U.S.C. 355(a)The product is misbranded—its label is false or misleading—because it does not disclose that it contains diclofenac and dexamethasone.
FD&C Act section 502(a), 21 U.S.C. 352(a)Selling or shipping the unapproved drug across state lines is prohibited.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)Selling or shipping the misbranded drug across state lines is prohibited.
FD&C Act section 301(a), 21 U.S.C. 331(a)
What FDA wants
FDA asks the company to submit a written response within 15 working days of receipt explaining the steps it has taken to fix the violations and prevent recurrence, with supporting documents.
Who should pay attention
- retailers and websites selling Artri or Ortiga joint products
- consumers who bought Artri King from Latin Foods Market
- distributors of supplement-style products that make drug claims
This is a summary. Read the original letter on fda.gov.